跳至主要内容
临床试验/CTRI/2026/03/105199
CTRI/2026/03/105199尚未招募不适用

Follow-the-Suture vs PREEMPT: A Comparative Study of OnabotulinumtoxinA Injection Methods for Chronic Migraine

ABVIMS AND Dr RML HOSPITAL1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2026年3月30日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
44
试验地点
1

研究概览

简要总结

OnabotulinumtoxinA is currently one of the therapies specifically approved for the prevention of chronic migraine. Its efficacy was firmly established in the pivotal Phase III PREEMPT (Phase 3 Research Evaluating Migraine Prophylaxis Therapy) trials, which demonstrated significant reductions in headache frequency and disability, alongside improvements in quality of life compared with placebo. There is a paucity of data comparing alternative techniques like Follow-the-suture method with PREEMPT protocol for administration of OnabotulinumtoxinA in patients with chronic migraine. Recent anatomical and experimental insights suggest that cranial sutures represent critical sites for nociceptive innervation, as meningeal collaterals traverse the skull through these junctions. Based on this rationale, an alternative injection approach termed the Follow-the-Sutures method has been proposed, wherein it is administered along cranial suture lines rather than muscle groups. This strategy may offer similar or improved efficacy. Herein we aim to compare, Follow-the-suture technique for administering OnabotulinumtoxinA to the PREEMPT method  in patients of Chronic Migraine.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Fulfilling diagnostic criteria for chronic migraine as per ICHD-
  • Patients who have been on at least one preventive medication for a minimum duration of 3 months, with no dose changes in the preceding month.
  • Patients willing to provide informed written consent.

排除标准

  • Prior neurological diseases such as brain tumors, dementia, seizures, encephalitis, meningitis, or stroke.
  • Patients failing to complete the headache diary for more than six non-consecutive days during the 28-day baseline period.
  • Patients unable to maintain a headache diary due to illiteracy or lack of caregiver support.
  • Patients with contraindications to OnabotulinumtoxinA injections (e.g., prior allergy, infection at injection site, neuromuscular disorders).
  • Pregnancy or lactation.

研究者

发起方
ABVIMS AND Dr RML HOSPITAL
申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Aktar Hussain Barbhuiya

Atal Bihari Vajpayee Institute of Medical Sciences and Dr. RML Hospital

研究点 (1)

Loading locations...

相似试验